L
Lin Xu
Researcher at Nanjing Medical University
Publications - 298
Citations - 11979
Lin Xu is an academic researcher from Nanjing Medical University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 43, co-authored 270 publications receiving 9263 citations. Previous affiliations of Lin Xu include China Pharmaceutical University.
Papers
More filters
Journal ArticleDOI
Serum MicroRNA Signatures Identified in a Genome-Wide Serum MicroRNA Expression Profiling Predict Survival of Non–Small-Cell Lung Cancer
Zhibin Hu,Xi Chen,Yang Zhao,Tian Tian,Guangfu Jin,Yongqian Shu,Yijiang Chen,Lin Xu,Ke Zen,Chen-Yu Zhang,Hongbing Shen +10 more
TL;DR: The four-miRNA signature from the serum may serve as a noninvasive predictor for the overall survival of NSCLC.
Journal ArticleDOI
Genetic variants of miRNA sequences and non-small cell lung cancer survival.
Zhibin Hu,Jiaping Chen,Tian Tian,Xiaoyi Zhou,Haiyong Gu,Lin Xu,Yi Zeng,Ruifen Miao,Guangfu Jin,Hongxia Ma,Yijiang Chen,Hongbing Shen +11 more
TL;DR: A systematic survey of common pre-miRNA SNPs and their surrounding regions found that the rs11614913 SNP in hsa-mir-196a2 was associated with survival in individuals with non-small cell lung cancer, and may be a prognostic biomarker for NSCLC.
Journal ArticleDOI
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy.
TL;DR: Current understanding of the tumorigenic significance, origin, and heterogeneity of CAFs, as well as the roles of different CAFs subtypes in distinct immune cell types are described.
Journal ArticleDOI
LncRNA HOXA11-AS Promotes Proliferation and Invasion of Gastric Cancer by Scaffolding the Chromatin Modification Factors PRC2, LSD1, and DNMT1.
Ming Sun,Ming Sun,Fengqi Nie,Yunfei Wang,Zhihong Zhang,Jiakai Hou,Dandan He,Min Xie,Lin Xu,Wei De,Zhaoxia Wang,Jun Wang +11 more
TL;DR: Findings support a model in which the EZH2/HOXA11-AS/LSD1 complex and HOXA 11- AS/miR-1297/EZh2 cross-talk serve as critical effectors in gastric cancer tumorigenesis and progression, suggesting new therapeutic directions in gastrics cancer.
Journal ArticleDOI
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Wen-Zhao Zhong,Qun Wang,Weimin Mao,Song-Tao Xu,Lin Wu,Yi Shen,Yongyu Liu,Chun Chen,Ying Cheng,Lin Xu,Jun Wang,Ke Fei,Xiaofei Li,Jian Li,Cheng Huang,Zhidong Liu,Shun Xu,Ke-Neng Chen,Shidong Xu,Lunxu Liu,Ping Yu,Bu-Hai Wang,H. Ma,Hong-Hong Yan,Xue-Ning Yang,Qing Zhou,Yi-Long Wu,Siyu Wang,Jian Hu,Wei Liu,Wei Li,Jianhua Shi +31 more
TL;DR: Adjuvant gefitinib led to significantly longer disease-free survival compared with that for vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant NSCLC.